KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Assets (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Non-Current Assets for 8 consecutive years, with $488.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 37.15% to $488.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, down 3.1% year-over-year, with the annual reading at $488.7 million for FY2025, 37.15% up from the prior year.
  • Non-Current Assets hit $488.7 million in Q4 2025 for Vir Biotechnology, up from $473.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $580.9 million in Q1 2024 to a low of $142.5 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $347.4 million across 5 years, with a median of $330.8 million in 2022.
  • Biggest five-year swings in Non-Current Assets: soared 167.39% in 2021 and later crashed 35.35% in 2025.
  • Year by year, Non-Current Assets stood at $391.4 million in 2021, then dropped by 27.7% to $283.0 million in 2022, then grew by 16.9% to $330.8 million in 2023, then increased by 7.71% to $356.4 million in 2024, then surged by 37.15% to $488.7 million in 2025.
  • Business Quant data shows Non-Current Assets for VIR at $488.7 million in Q4 2025, $473.8 million in Q3 2025, and $456.8 million in Q2 2025.